Return to study ST000525 main page

MB Sample ID: SA027585

Local Sample ID:ms5589-19
Subject ID:SU000547
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human

Select appropriate tab below to view additional metadata details:


Subject:

Subject ID:SU000547
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human

Factors:

Local Sample IDMB Sample IDFactor Level IDLevel ValueFactor Name
ms5589-19SA027585FL006884Old-Placebogroup
ms5589-19SA027585FL006884PreTime point

Collection:

Collection ID:CO000541
Collection Summary:Healthy men & women aged 45-79 without clinical CVD, but with below normal baseline endothelial dysfunction (FMDBA < 7%).
Sample Type:Blood

Treatment:

Treatment ID:TR000561
Treatment Summary:A 12-week randomized, double-blind, placebo controlled study will be conducted. After CTRC screening for inclusion/exclusion criteria, qualified subjects will be randomly assigned to 1 of 2 groups. The investigators involved in the acquisition and analysis of key outcomes will be blinded to the curcumin intake status of the subjects. With the assistance of dietary monitoring from the UC-Boulder CTRC bionutritionists, subjects will maintain their baseline diet with either unchanged (control) or enhanced curcumin intake delivered as capsules (Longvida®, Verdure Sciences): Group 1 = placebo (inert substances); Group 2 = curcumin (2000mg curcumin/day). Extensive published work has established that the curcumin dose of 2000 mg/day is well tolerated and safe. Sessions 1 & 2: Screening measurements. Session 3: Baseline measurements and blood draw. Sessions 4-8 (every other week to assess adherence and overall subject well-being): Body weight, BP, adherence, discuss any problems. Session 9: Identical to session 3 (stop intake of capsules after completion of post-testing).

Sample Preparation:

Sampleprep ID:SP000554
Sampleprep Summary:Venous blood sampling. All blood samples are handled in a similar time frame and immediately spun to extract plasma and stored in our -80 freezer until ready for analysis. NEFA concentrations were measured.

Combined analysis:

Analysis ID AN000803
Analysis type MS
Chromatography type Reversed phase
Chromatography system Agilent 1290 Infinity
Column Waters Acquity BEH C18 (150 x 2.1mm,1.7um)
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name Agilent 6460 QQQ
Ion Mode POSITIVE
Units uM

Chromatography:

Chromatography ID:CH000578
Instrument Name:Agilent 1290 Infinity
Column Name:Waters Acquity BEH C18 (150 x 2.1mm,1.7um)
Chromatography Type:Reversed phase

MS:

MS ID:MS000710
Analysis ID:AN000803
Instrument Name:Agilent 6460 QQQ
Instrument Type:Triple quadrupole
MS Type:ESI
Ion Mode:POSITIVE
  logo